WorldCat Identities

Wang, Ena

Overview
Works: 110 works in 149 publications in 3 languages and 934 library holdings
Roles: Editor, Contributor, Author, Other, htt
Classifications: QR181, 616.079
Publication Timeline
.
Most widely held works by Ena Wang
Immunologic signatures of rejection by Francesco M Marincola( )

14 editions published between 2010 and 2011 in English and German and held by 444 WorldCat member libraries worldwide

This book collects salient observational data, derived predominantly from human studies, regarding the mechanism(s) of rejection in various pathologic conditions; the premise is that immune rejection, better defined as "immune-mediated, tissue-specific destruction" (TSD), comprises a broad range of phenomena ranging from tumor regression, to clearance of pathogen through destruction of infected cells, autoimmunity, allograft rejection by the host and host versus graft reactions. Like different hands can turn on or off a switch, distinct mechanisms can trigger TSD; however, a convergent pathway is ultimately observed when TSD occurs consisting of a dramatic switch from chronic to acute inflammation leading to the activation of a restricted number of genes that we comprise in the immunologic constant of rejection (ICR) model. Although the ICR model does not address "why" rejection occurs but rather "how", and it may not contribute an explanation for the determinism of rejection, it provides, if correct, a simplified road map about the convergent pathways leading to TSD. This offers the opportunity to identify a common target for immune manipulation with therapeutic purposes since ICR-related pathways are restricted in expression to the tissues in which TSD occurs while are shut off in the rest of a normal organism. The book includes chapters from outstanding basic and/or observational scientists that have contributed to this area either by defining mechanisms relevant to the understanding of the inflammatory switch or by describing how this occurs in human tissues under different pathological conditions. We would like to entice our reader(s) to test with us, through, the readings, whether our hypothesis is correct; we predict that common themes will emerge particularly if attention will be paid to the general phenomenon of TSD rather than the peculiarities of individual pathologies. With the hope of having contributed with this book something novel and important and we wish our reader a pleasant journey in the wondrous land of immune-mediated, tissue-specific destruction
Developments in T cell based cancer immunotherapies by Paolo A Ascierto( )

16 editions published in 2015 in English and held by 264 WorldCat member libraries worldwide

This volume illustrates the salient aspects of cancer biology relevant to the successful implementation of immunotherapy. Topics include enhancement of antigen-specific immune responses by anti-cancer vaccines, modulation of the function of T cells within the tumor microenvironment, and the effects of genetic, epigenetic, developmental, and environmental determinants on T cell function. Other topics covered include the ex vivo expansion of T or other immune cells and their genetic modification or reprogramming to increase their ability to survive and expand when adoptively transferred back to the patients. Specific attention is devoted to the genetic manipulation of T cells through the introduction of re-directed T cell receptors, chimeric antibody receptors, and other genetic manipulation aimed at improving their effectiveness as anti-cancer agents. Furthermore, the revolutionary role of checkpoint inhibitors and their potential in combination with other immunotherapeutic approaches or with standard chemo and radiation therapy are extensively discussed
The stable traits of melanoma genetics: an alternate approach to target discovery by Tara L Spivey( )

2 editions published between 2012 and 2016 in English and held by 4 WorldCat member libraries worldwide

De guo zhi ye jiao yu jiao xue fa zhi li lun yu an li by Ena Wang( Book )

3 editions published between 2015 and 2016 in Chinese and held by 4 WorldCat member libraries worldwide

Ben shu ji yu xing dong wei dao xiang de xian dai zhi jiao li nian,Zhong dian ju jiao yu de guo zhi ye jiao yu jiao xue fa zhi li lun tan tao yu an li yan jiu.Cong li lun jiao xue yu shi jian jiao xue liang ge fang mian dui yu de guo zhi ye jiao yu de jiao xue fa,Fang fa lun jun ji chu le jie shao
Fu mu jiao se : Wei shen me wo men de jiao yu fang fa ru ci bu tong by Yolanda Cadalbert-Schmid( Book )

3 editions published in 2002 in Chinese and held by 4 WorldCat member libraries worldwide

Ben shu dui fu mu qin jiao yu hai jin xing le pou xi,Bing dui fu mu de lei xing jin xing hua fen deng
Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection by Stephanie Weibel( )

2 editions published between 2011 and 2012 in English and held by 4 WorldCat member libraries worldwide

<> by Maria L Ascierto( )

2 editions published in 2013 in English and held by 4 WorldCat member libraries worldwide

<> by Ileana S Mauldin( )

2 editions published in 2013 in English and held by 4 WorldCat member libraries worldwide

Cancer classification using the Immunoscore: a worldwide task force by Jerome Galon( )

2 editions published in 2012 in English and held by 3 WorldCat member libraries worldwide

Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the ` Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)
An immunologic portrait of cancer by Maria Libera Ascierto( )

1 edition published in 2011 in English and held by 2 WorldCat member libraries worldwide

Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer by Lance D Miller( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma by Valeria De Giorgi( )

1 edition published in 2009 in English and held by 2 WorldCat member libraries worldwide

Selection and validation of endogenous reference genes using a high throughput approach by Ping Jin( )

1 edition published in 2004 in English and held by 2 WorldCat member libraries worldwide

Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis by Ping Jin( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012" by Paolo A Ascierto( )

1 edition published in 2013 in English and held by 2 WorldCat member libraries worldwide

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration by Monica C Panelli( )

1 edition published in 2004 in English and held by 2 WorldCat member libraries worldwide

CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer by Maciej Kmieciak( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

Potency analysis of cellular therapies: the emerging role of molecular assays by David F Stroncek( )

1 edition published in 2007 in English and held by 2 WorldCat member libraries worldwide

Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine by Mengjia Qian( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy by Marie-Andrée Forget( )

1 edition published in 2013 in English and held by 2 WorldCat member libraries worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.50 (from 0.45 for Immunologi ... to 0.97 for Immunologi ...)

WorldCat IdentitiesRelated Identities
Immunologic signatures of rejection
Covers
Languages